New York, NY - Altaris, LLC (collectively with its managed funds, “Altaris”), announced today that it has completed the combination of its operating companies, Minaris Regenerative Medicine and Advanced Therapies. This combination creates a leading contract development and manufacturing organization (“CDMO”) with an ability to deliver life-changing cell and gene therapies to patients on a global basis. The combined company will operate under the name Minaris Advanced Therapies and will be headquartered in Philadelphia, Pennsylvania.
Minaris Advanced Therapies is a global CDMO and contract testing provider focused exclusively on cell and gene therapies. The company has more than 730,000 square feet of clinical and commercial infrastructure across the United States, Europe and Asia, and has manufactured and released more than 7,500 GMP batches over its 25-year history. The company offers a complete cell and gene therapy outsourcing solution to its customers from early-stage development through clinical trials and commercial manufacturing. Please visit to learn more.
Altaris has a long history of investing in the medical product CDMO sector and is well-positioned to support Minaris Advanced Therapies over the next phase of its growth.
Advisors
Kirkland & Ellis LLP acted as legal counsel for Altaris.
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com.